Decitabine Combined With Unrelated Cord Blood Transplantation for Elderly Patients With AML

Multicenter, One-arm, Phase II Clinical Study of Decitabine Combined With Unrelated Cord Blood Transplantation for the Treatment of Acute Myeloid Leukemia (AML) in the Elderly

Status

UNKNOWN

Phases

Phase 1Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03913312

Enrollment

150

Registered

2019-04-12

Start date

2018-09-01

Completion date

2022-09-30

Last updated

2019-07-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Myeloid Leukemia

Keywords

AML,Elderly patients,Decitabine,Unrelated cord blood

Brief summary

Acute myeloid leukemia (AML) is a clonal disease caused by genetic mutations in Hematopoietic stem progenitor cells. Unfortunately, advanced age (\>60 years old) is considered to be one of the most important adverse prognostic factors for AML, and older patients are unable to tolerate high-dose chemotherapy, due to various complications and organ dysfunction. Based on the results of the previous research, we will carry out the pretreatment regimen of decitabine + cytarabine in elderly patients with AML who have achieved disease treatment through induction therapy, and continue the transplantation program of unrelated-blood cord blood. By assessing the patient's DFS,OS,RFS and safety to determine whether the regimen is suitable for the consolidation treatment of elderly acute myeloid leukemia, further clarify the efficacy of this regimen compared with traditional consolidation therapy, and initially confirm the effect of combined with unrelated cord blood transplantation in the treatment of acute myeloid leukemia.

Detailed description

A prospective,Multicenter,open,single-arm clinical study.The research process is divided into three phases: the screening phase, the treatment phase, and the follow-up phase. The treatment phase includes pre-transplant pretreatment, cord blood transplantation, and consolidation therapy.

Interventions

BIOLOGICALUnrelated cord blood

Unrelated cord blood comes from Shandong cord blood bank. TNC\>1.5\*107/kg;HLA 4-5/6

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

60 Years to 75 Years

Healthy volunteers

Inclusion criteria

1. AML patients diagnosed by bone marrow morphology and Immunology; 2. Exclusion of APL by Bone marrow morphology or molecular level; 3. A patient who has obtained bone marrow cytology remission after inductive treatment; 4. Aged from 60 to 75 years; 5. Liver and kidney function: blood bilirubin ≤ 35μmol / L, AST or/ALT \<2 times the upper limit of normal (ULN), serum creatinine;≤ 150μmol / L; 6. The function of Heart is normal; 7. Physical condition score 0-2 (ECOG score); 8. Get informed consent signed by patient or family member.

Exclusion criteria

1. APL patients, treatment-related AML; 2. Retreatment of patients; 3. Allergies to any of the drugs involved in the protocol; 4. There are obvious contraindications to chemotherapy drugs; 5. Liver and kidney function is obviously abnormal, exceeding the inclusion criteria; 6. Serious heart disease, including myocardial infarction, cardiac insufficiency; 7. Suffering from other organ malignant tumors at the same time ; 8. Active period of tuberculosis patients and HIV-positive patients; 9. Suffering from other blood system diseases at the same time; 10. Pregnancy or breastfeeding; 11. Cannot understand or follow the research plan; 12. A history of intolerance or allergies to similar drugs; 13. Patients under 60 years of age or over 75 years of age; 14. Participate in other clinical researchers at the same time; 15. There are other situations that hinder the conduct of the study.

Design outcomes

Primary

Measure	Time frame
Disease free survival (DFS)	Three years

Secondary

Measure	Time frame	Description
Overall Survival (OS)	Three years	The time from enrollment to death for any reason
Complete Remission Rate (CR)	Three years	The proportion of cases of hematologic remission that reached the total
Adverse Events (refer to National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE] version 4.03).	Three years	Safety/Toxicity Monitoring

Countries

China

Contacts

Primary ContactJunmin Li

drlijunmin@126.com86-21-64374756

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026